Table 1.

Medications used to treat motor symptoms associated with HD

	Class	Name	Evidence
Drugs approved by the FDA for HD	VMAT2 inhibitor	Tetrabenazine	- Efficacious in reducing hyperkinetic movements - Associated with side-effects
		Deutetrabenazine	- Efficacious in reducing hyperkinetic movements - Associated with less side-effects than TBZ
FDA-approved drugs, but not specifically for HD (off-label use)	Antipsychotic	Aripiprazole	- Showed therapeutic potential in reducing chorea - No efficacy in improving cognition
		Haloperidol	- Some effectiveness in reducing chorea - Some effectiveness in reducing mutant huntingtin aggregate formation in rats - No improvement of functional capacity
		Risperidone	- Some effectiveness in improving motor symptoms
		Clozapine	- No effectiveness in reducing chorea (but controversial, probably on higher doses, but it increases side-effects)
	Dopaminergic stabiliser	Pridopidine	- In development for HD - Reduced UHDRS-modified motor score, but not TMS (only with higher doses, which caused more side-effects)